News | July 18, 2022
Glaucoma Research Foundation launches catalyst for a to prevent and cure neurodegeneration
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
George Svokos joins Avet after serving as a strategic business advisor to numerous global healthcare companies
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Subscribe To Our Newsletter & Stay Updated
